<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="821">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583410</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200538</org_study_id>
    <secondary_id>2020-003722-23</secondary_id>
    <nct_id>NCT04583410</nct_id>
  </id_info>
  <brief_title>Efficacy of Nicotine in Preventing COVID-19 Infection in Caregivers</brief_title>
  <acronym>NICOVID-PREV</acronym>
  <official_title>Efficacy of Nicotine in Preventing COVID-19 Infection in Caregivers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The coronavirus disease (COVID-19) epidemic represents a major therapeutic challenge. The&#xD;
      highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and the long&#xD;
      duration of the disease have led to a massive influx of patients admitted in health services&#xD;
      and intensive care units. These patients represent a significant infection risk to the&#xD;
      medical staff. According to current knowledge, there are no treatments that prevent the&#xD;
      spread of the infection, especially in exposed populations, or the disease progression to a&#xD;
      severe form.&#xD;
&#xD;
      Daily active smokers are infrequent among outpatients or hospitalized patients with COVID-19.&#xD;
      Several arguments suggest that nicotine is responsible for this protective effect via the&#xD;
      nicotinic acetylcholine receptor (nAChR).&#xD;
&#xD;
      Nicotine may inhibit the penetration and spread of the virus and have a prophylactic effect&#xD;
      in COVID-19 infection, especially in healthcare workers who are at high risk of infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-COV2 seroconversion between W0 and W19 after randomization</measure>
    <time_frame>Between week 0 and week 19</time_frame>
    <description>This is the proportion of patients with at least one positive serology between W2 and W19. The time of S19 takes into account a seroconversion delay of 5 weeks in relation to the SARS-CoV2 contamination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of documented symptomatic COVID-19 infection</measure>
    <time_frame>Week 8, Week16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-COV2 seroconversion</measure>
    <time_frame>Week 16</time_frame>
    <description>This is the proportion of patients with at least one positive serology between W2 and W16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic COVID-19 infection proportion at week 14</measure>
    <time_frame>Week 14</time_frame>
    <description>Asymptomatic COVID-19 infection is defined as SARS-CoV2 seroconversion at Week 19 without symptoms suggestive of COVID until the end of Week 16 to take in account of the two weeks of incubation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of severe COVID-19 infection</measure>
    <time_frame>Week 8, Week16</time_frame>
    <description>documented infection (positive SARS-CoV2 PCR test and / or suggestive chest CT scan and / or seroconversion) whose first symptoms appeared before W8 and W16 respectively, and requiring hospitalization or home oxygen therapy, or having resulted in death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sick leaves for a COVID-19 infection</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days off during sick leaves for a COVID-19 infection</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of AE, SAE</measure>
    <time_frame>From inclusion and week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity and frequency of nausea, dizziness, feeling of empty head, headache, vomiting</measure>
    <time_frame>Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of active smoker or active vapers or taking nicotine substitutes documented by examination</measure>
    <time_frame>Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of active smoker or active vapers or taking nicotine substitutes documented by urinary cotinine</measure>
    <time_frame>Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score of Desire to smoke defined by French Tobacco Craving scale</measure>
    <time_frame>Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score of Withdrawal symptoms scale</measure>
    <time_frame>Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of cotinine in the urine</measure>
    <time_frame>Week 8 and 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score of Fatigue Numeric rating scale</measure>
    <time_frame>Week 2, week 8, week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Week 8, week 16, week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score of Hospital anxiety and depression scale</measure>
    <time_frame>Week 2, week 8, week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score of Insomnia severity scale</measure>
    <time_frame>Week 2, week 8, week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and negative syndrome scale</measure>
    <time_frame>Week 2, week 8, week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1633</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere</condition>
  <arm_group>
    <arm_group_label>Nicotine patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patch</intervention_name>
    <description>NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day&#xD;
Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day</description>
    <arm_group_label>Nicotine patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>PLACEBO OF NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day&#xD;
Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day</description>
    <arm_group_label>Placebo patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospital staff in contact with patients&#xD;
&#xD;
               1. doctors, nurses, caregivers, physiotherapists, stretcher bearers, radio&#xD;
                  manipulators, etc.&#xD;
&#xD;
               2. active on health institution (not teleworking) for the duration of the study&#xD;
                  (health students are eligible if their internship covers the entire duration of&#xD;
                  the study)&#xD;
&#xD;
               3. can be followed for the duration of the study&#xD;
&#xD;
          2. aged 18 or over&#xD;
&#xD;
          3. Obtaining free, informed and signed consent&#xD;
&#xD;
          4. Affiliated to a social security scheme or beneficiary of such a scheme (except AME)&#xD;
&#xD;
          5. non-smoker and non-vaping (for former smokers or vapers: abstinent for at least 12&#xD;
             months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptoms suggestive of COVID-19 on the day of inclusion or in the past 14 days&#xD;
&#xD;
          2. Documented history of COVID-19 and / or positive SARS-COV2 serology before the day of&#xD;
             inclusion&#xD;
&#xD;
          3. Treatment ongoing with nicotine replacement therapy, varenicline or bupropion within&#xD;
             30 days before inclusion&#xD;
&#xD;
          4. Known addiction problem to alcohol (defined by AUDIT-C &gt; or = 10) or other substances.&#xD;
&#xD;
          5. Contraindications for nicotine patches:&#xD;
&#xD;
               -  pregnant woman (negative pregnancy test on inclusion) or breastfeeding woman&#xD;
&#xD;
               -  lack of effective contraception for women of childbearing potential&#xD;
&#xD;
               -  Generalized skin conditions that can interfere with the use of a transdermal&#xD;
                  patch&#xD;
&#xD;
               -  stroke or myocardial infarction or acute coronary syndrome for less than 3 months&#xD;
&#xD;
               -  allergy to nicotine or to one of the excipients of the transdermal patch&#xD;
&#xD;
               -  Uncontrolled high blood pressure&#xD;
&#xD;
               -  Unstable or worsening angor&#xD;
&#xD;
               -  Severe cardiac arrhythmia (defined by wearing an automatic implantable&#xD;
                  defibrillator)&#xD;
&#xD;
               -  Obliterating peripheral arterial disease&#xD;
&#xD;
               -  Known severe heart failure&#xD;
&#xD;
               -  Known severe renal or hepatic impairment,&#xD;
&#xD;
               -  Pheochromocytoma&#xD;
&#xD;
               -  Uncontrolled hyperthyroidism&#xD;
&#xD;
               -  Esophagitis due to gastroesophageal reflux disease or active peptic ulcer&#xD;
&#xD;
                  6 Already included in an interventional trial evaluating a health product 7 Staff&#xD;
                  under guardianship or curatorship or deprived of their liberty by a judicial or&#xD;
                  administrative decision 8 Do not have a smartphone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zahir AMOURA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zahir AMOURA, MD</last_name>
    <phone>+33142178244</phone>
    <email>zahir.amoura@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence TUBACH, MD</last_name>
    <email>florence.tubach@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Gonesse</name>
      <address>
        <city>Gonesse</city>
        <zip>95500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle AMOURA, MD</last_name>
      <email>isabelle.amoura@ch-gonesse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier de la Région de Mulhouse Sud Alsace</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guylaine LABRO, MD</last_name>
      <email>guylaine.labro@ghrmsa.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière - Service de Médecine Interne</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zahir AMOURA, MD</last_name>
      <email>zahir.amoura@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raphael GAILLARD, MD</last_name>
      <email>r.gaillard@ghu-paris.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>SARS-COV2</keyword>
  <keyword>Preventing infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

